Seeking Alpha

nbm

nbm
Send Message
View as an RSS Feed
View nbm's Comments BY TICKER:
Latest  |  Highest rated
  • IsoRay's Cesium-131 Long Awaited Lung Study Results Appear To Be Coming May 8th [View article]
    Nice Results PR today.. Excellent volume and price action too.
    Todd,Thanks for your article from the 29th. Are you planning any more?
    May 20, 2015. 02:23 PM | 1 Like Like |Link to Comment
  • IsoRay's Cesium-131 Long Awaited Lung Study Results Appear To Be Coming May 8th [View article]
    PR on Monday highlights glowing reviews of Cesium 131


    IsoRay's Cesium-131 Cancer Treatment Takes Center Stage at Weill Cornell's International Symposium "Advances in Brachytherapy"
    Successful Cesium-131 Cancer Treatment Results, Methods and Patient Selection Criteria Were Presented in a Peer to Peer Forum of Leading Medical Professionals
    Marketwired IsoRay, Inc.
    May 11, 2015 8:30 AM

    

    RICHLAND, WA--(Marketwired - May 11, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that a number of industry leaders discussed the successes achieved by their patients in a variety of body sites being treated with IsoRay's Cesium-131 internal radiation (brachytherapy) cancer seeds at the "Advances in Brachytherapy" symposium, held at Weill Cornell on Friday and Saturday.

    IsoRay Chairman and CEO Dwight Babcock commented, "We are so very pleased to have studies presented reporting successes in peer to peer presentations. Data from ongoing studies continues to be gathered and when it matures the expectation is that it will be peer reviewed and published. We are now hearing from more institutions based on our new recently released peer reviewed publications. Medical professionals rely on these publications to further their practice and learn about new leading edge products."

    NOTES FROM THE FIELD AT THE SYMPOSIUM

    1.) LDR Brachytherapy: MD Anderson Experience - Steve Frank, M.D.

    Dr. Frank discussed the ongoing prostate cancer trial at MD Anderson Cancer Center in Houston, including the use of Cesium-131 as treatment. He also discussed the emerging use of magnetic resonance (MR) imaging in determining radiation doses delivered following prostate brachytherapy. Cesium-131 was the first isotope chosen to be used in conjunction with the MRI spacer.

    2.) Role of Brachytherapy in Recurrent H&N Cancers - Bhupesh Parashar, M.D.

    Dr. Parashar discussed the option of Cesium-131 brachytherapy as part of the management of recurrent head and neck cancers. Details on this study were recently presented at the 97th Annual Meeting of the American Radium Society.

    3.) Resection with intraoperative Cs-131 Brachytherapy in Newly Diagnosed Brain Metastases and Recurrent GBM: Techniques and Outcomes - Theodore Schwartz, M.D. and A. Gabriella Wernicke, M.D.

    Drs. Schwartz and Wernicke described their study, published recently in the Journal of Neurosurgery, where very high rates of control have been seen in the treatment of metastatic brain cancer. In particular they noted the benefit of Cesium-131 treatment in tandem with surgery over waiting weeks or months to perform other types of radiation treatment. Their group continues to add patients to their existing study and they are planning a trial to compare Cesium-131 treatment to other radiation treatments in the treatment of brain metastases.

    4.) Impact of Brachytherapy on Local Recurrence Rates after Sublobar Resection in Early Stage Non-Small Cell Lung Cancer - Bhupesh Parashar, M.D.

    Dr. Parashar discussed the role of Cesium-131 brachytherapy in addition to lung sparing wedge resection surgery for patients with operable lung cancers. Although there is some discussion ongoing regarding the use of brachytherapy in these cases, Dr. Parashar stated that he continues to see the value of Cesium-131 brachytherapy for appropriately selected patients.

    IsoRay Chairman and CEO Dwight Babcock noted, "Cesium-131 continues to impress medical professionals as reported successes are showing positive results in treating some of the toughest cancer cases. Many of our cases are brought by physicians seeking solutions where first line treatments have failed. Following Cesium-131 treatment, patients are having better outcomes with improved quality of life. Therapy with Cs-131 is successfully treating patients who failed conventional therapies and we believe that it could help many other patients. We are extremely excited to see that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life."

    IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.

    About IsoRay
    IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting http://www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

    Safe Harbor Statement

    Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of our products will increase or continue, whether we will continue to receive support from industry leaders, whether awareness and adoption of our products in the medical community will continue or increase, whether ultimate study results will be favorable or will ultimately be peer reviewed and published, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
    Contact:

    IsoRay Medical
    Info@Isoray.com
    (509) 375-1202
    Or
    Worldwide Financial
    Info@wwfinancial.com
    (954) 360-9998
    May 13, 2015. 02:46 PM | 1 Like Like |Link to Comment
  • IsoRay's Cesium-131 Long Awaited Lung Study Results Appear To Be Coming May 8th [View article]
    Yes, Thank you very much.
    Will you be attending and issuing another report?
    Apr 30, 2015. 08:12 AM | 1 Like Like |Link to Comment
  • IsoRay's Cesium-131 Long Awaited Lung Study Results Appear To Be Coming May 8th [View article]
    Additionally, ISR is exhibiting and presenting at AANS Annual Scientific Meeting

    The American Association of Neurological Surgeons (AANS) Annual Scientific Meeting is the world's premier neurosurgical event. We are anticipating over 3,000 neurosurgeons and other healthcare professionals. This year's program will include an international symposium, superb invited speakers, practical clinics, breakfast seminars and 3D Sessions in addition to oral paper presentations and electronic poster presentations.


    What are the exhibition dates and times for the 2015 AANS Annual Scientific Meeting?
    Monday, May 4 9:00 a.m. - 4 p.m.
    Tuesday, May 5 9:00 a.m. - 4 p.m.
    Wednesday, May 6 9:00 a.m. - 2:15 p.m.

    Where are the exhibits located?
    The exhibits are located in the Walter E. Washington Convention Center.

    What is the address of the convention center?
    Walter E. Washington Convention Center
    801 Mt. Vernon Place, NW
    Washington, D.C.
    Apr 29, 2015. 02:16 PM | Likes Like |Link to Comment
  • IsoRay's Cesium-131 Long Awaited Lung Study Results Appear To Be Coming May 8th [View article]
    Great article. I have not seen such positive information on this company in awhile. As a shareholder I am pleased with your report. But I am curious about something you said. Quote: "with its issued patents and FDA approval for several types of cancer, IsoRay is protected from other competitors entering the market. Therefore, giving it a monopoly in the market."

    Could you explain how is it protected? There are other companies doing Brachytherapy such as CR Bard and Theragenics. And there is a small start up company, Advanced Medical presently awaiting FDA approval on their device.

    Thanks in advance.

    By the way, will you be attending the conference and reporting back to us the results?
    Apr 29, 2015. 01:32 PM | 1 Like Like |Link to Comment
  • Why Senesco Could Go From $2.50 To Over $10  [View instapost]
    amonge...
    Nice spike in ISR today... news on brain tumor treatment on child in Peru
    Jul 14, 2014. 10:19 AM | Likes Like |Link to Comment
  • Amarin Scrapes The Bottom Of The Barrel [View article]
    Pawn Stars is still being shown in the evenings. As a matter of fact, they are on Saturday Night (tomorrow) from 7 PM until about 3 AM. An I a m pretty sure they are on other evenings as well.
    My question is will AMRN actually be advertising on the show or even utilizing product placement of Vascepa in the new shows....Very easy to place a bottle on the shelf behind them or even on Rick's Desk when they show the back office.
    Jun 27, 2014. 10:02 AM | 2 Likes Like |Link to Comment
  • Top 10 Plays For Next Week's Russell Rebalancing [View article]
    So you are saying the funds will not be buying these shares until after the close of business Friday?
    Jun 23, 2014. 10:11 AM | 1 Like Like |Link to Comment
  • Top 10 Plays For Next Week's Russell Rebalancing [View article]
    What is the time frame that the funds must purchase these shares? Have they started already? Can they add over a period of time (how long), or do all shares get added on Friday during the day or after the close of business?
    Jun 22, 2014. 10:06 AM | Likes Like |Link to Comment
  • ZTE Settlement Could Drive Vringo Shares Substantially Higher [View article]
    Sujan,
    Thanks for this update.
    Another clear and concise review by you!
    NBM
    Jun 11, 2014. 11:25 AM | 3 Likes Like |Link to Comment
  • Isoray: Impressive 98% Success Treating Prostate Cancer [View article]
    John,
    Benzinger posted today (6/5/14) that they were hearing "chatter" that JnJ was showing interest in ISR. Did you hear anything, and if so what can you share with your readers and followers?
    TIA
    Jun 5, 2014. 05:55 PM | Likes Like |Link to Comment
  • Join My Free Stock Pick Alert Service [View instapost]
    Just signed up. thanks..
    What are your thoughts on ISR, now? Anymore left in the tank?
    May 7, 2014. 11:36 AM | Likes Like |Link to Comment
  • Ed Quilty, CEO Of Derma Sciences, Outlines His Strategy To Build A Premier Wound Healing Company [View article]
    What is your opinion on how this company compares to Alliqua (OTCQB:ALQA) which has received financing from and entered into a licensing agreement with Celgene? I understand their new product Biovance (from another SA author) is ready to launch in the second half of 2014.
    May 3, 2014. 07:26 PM | Likes Like |Link to Comment
  • Why IsoRay Presents A Very Compelling Risk/Reward Opportunity [View article]
    I would guestimate within 2 years based on the article, if its not bought out first! But I would like to hear the author's response to that question too.
    Great article.
    Mar 14, 2014. 12:21 PM | 2 Likes Like |Link to Comment
  • Growlife - It's All Smoke And Mirrors: Research Uncovers Why Shares Are Overhyped And Overvalued [View article]
    Just getting interested in this sector.. Thanks for everyone's comments. Did anyone hear of Inergetics (OTCQB:NRTI)? They just entered into a partnership with Terra Tech Corp (OTCQB:TRTC) to manufacture a line of natural Cannibidiol based nutritional supplements. The featured active ingredient in this new product line will be Cannibidiol (CBD), a non-psychoactive component of cannabis that possesses a wide range of therapeutic benefits. The supplements will be initially marketed to consumers of medical cannabis in legally approved markets who suffer from nausea and/or illnesses such as glaucoma, and who can benefit from CBD's pain management and other therapeutic properties. TIA
    Feb 6, 2014. 04:53 PM | 3 Likes Like |Link to Comment
COMMENTS STATS
39 Comments
30 Likes